Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07593092 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
A Phase 1 study, sponsored by Xencor.
- Not yet
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT07593092 is a Phase 1 study that has not yet begun recruiting, run by Xencor. The registered enrollment target is 90 participants.
The verdict
NCT07593092, a Phase 1 study, has not yet begun recruiting, sponsored by Xencor.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether the investigational drug XmAb541 in combination with XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on tumor outcomes.
Interventions
- BIOLOGICAL XmAb541
- BIOLOGICAL XmAb808
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07593092
The ClinicalTrials.gov registry entry for NCT07593092 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XmAb541 is the first listed.
NCT07593092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07593092 about?
NCT07593092 is a clinical study titled "Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors". The primary purpose of this study is to determine whether the investigational drug XmAb541 in combination with XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on tumor o...
What is the current status of trial NCT07593092?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2026-06. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07593092?
The interventions under investigation include: XmAb541 (BIOLOGICAL), XmAb808 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07593092?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.